Posted by Michael Wonder on 01 Feb 2023
FLAG Therapeutics receives rare paediatric disease designation for FLAG-003 for the treatment of children with diffuse intrinsic pontine glioma
31 January 2023 - FLAG Therapeutics announced today that FLAG-003, an investigational small molecule therapy for the treatment of diffuse intrinsic pontine glioma, a rare, highly aggressive and difficult to treat brain tumour found in children, has been granted rare paediatric disease designation from the US FDA.
FLAG-003, the company’s lead program for the treatment of all gliomas, is engineered to cross the blood brain barrier and specifically target and kill cancer cells by simultaneously blocking the formation of a tumour vascular system and disrupting cancer cell replication by inhibiting tubulin.
